Evidence map›Paper›PMID 33062139›Full record

ArticleOxidative medicine and cellular longevity2020

Bakuchiol Alleviates Hyperglycemia-Induced Diabetic Cardiomyopathy by Reducing Myocardial Oxidative Stress via Activating the SIRT1/Nrf2 Signaling Pathway.

Wenshuai Ma, Wangang Guo, Fujun Shang, Yan Li, Wei Li, Jing Liu, Chao Ma, Jiwei Teng

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 73 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Epigenetic Mechanisms in Heart Diseases.Reviews in cardiovascular medicine · 2025
    Review
  6. Review
  7. Shikonin attenuates blood-brain barrier injury and oxidative stress in rats with subarachnoid hemorrhage by activating Sirt1/Nrf2/HO-1 signaling.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025
    Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wenshuai MaDepartment of Cardiology, Second Affiliated Hospital, The Air Force Medical University, 1 Xinsi Road, Xi'an 710038, China.
Wangang GuoDepartment of Cardiology, Second Affiliated Hospital, The Air Force Medical University, 1 Xinsi Road, Xi'an 710038, China.
Fujun ShangDepartment of Cardiology, Second Affiliated Hospital, The Air Force Medical University, 1 Xinsi Road, Xi'an 710038, China.
Yan LiDepartment of Cardiology, Second Affiliated Hospital, The Air Force Medical University, 1 Xinsi Road, Xi'an 710038, China.
Wei LiDepartment of Cardiology, Second Affiliated Hospital, The Air Force Medical University, 1 Xinsi Road, Xi'an 710038, China.
Jing LiuDepartment of Cardiology, Second Affiliated Hospital, The Air Force Medical University, 1 Xinsi Road, Xi'an 710038, China.
Chao MaDepartment of Cardiology, Second Affiliated Hospital, The Air Force Medical University, 1 Xinsi Road, Xi'an 710038, China.
Jiwei TengDepartment of Cardiology, Second Affiliated Hospital, The Air Force Medical University, 1 Xinsi Road, Xi'an 710038, China.ORCID https://orcid.org/0000-0003-0992-814X
Air Force Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bakuchiol (BAK), a monoterpene phenol reported to have exerted a variety of pharmacological effects, has been related to multiple diseases, including myocardial ischemia reperfusion injury, pressure overload-induced cardiac hypertrophy, diabetes, liver fibrosis, and cancer. However, the effects of BAK on hyperglycemia-caused diabetic cardiomyopathy and its underlying mechanisms remain unclear. In this study, streptozotocin-induced mouse model and high-glucose-treated cell model were conducted to investigate the protective roles of BAK on diabetic cardiomyopathy, in either the presence or absence of SIRT1-specific inhibitor EX527, SIRT1 siRNA, or Nrf2 siRNA. Our data demonstrated for the first time that BAK could significantly abate diabetic cardiomyopathy by alleviating the cardiac dysfunction, ameliorating the myocardial fibrosis, mitigating the cardiac hypertrophy, and reducing the cardiomyocyte apoptosis. Furthermore, BAK achieved its antifibrotic and antihypertrophic actions by inhibiting the TGF-

Indexed as

AnimalsAntioxidantsCarbazolesCell SurvivalCollagenDiabetes Mellitus, ExperimentalDiabetic CardiomyopathiesGlucoseMaleMiceMice, Inbred C57BLMyocardiumMyocytes, CardiacNF-E2-Related Factor 2Oxidative StressPhenols6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamideAntioxidantsbakuchiolCarbazolesCollagenGlucoseNF-E2-Related Factor 2PhenolsRNA, Small InterferingSirtuin 1

Identifiers

PMID33062139
PMCPMC7545423
OpenAlexW3090366515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.